Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Corticospinal tract integrity is related to primary motor cortex thinning in relapsing-remitting multiple sclesis.
[Need for creating Polish registry of multiple sclerosis patients].
[Animal models for multiple sclerosis].
Investigating Tissue Optical Properties and Texture Descriptors of the Retina in Patients with Multiple Sclerosis.
Oligodendroglial defects during quakingviable cerebellar development.
Meningoencephalitis-like onset of post-infectious AQP4-IgG-positive optic neuritis complicated by GM1-IgG-positive acute polyneuropathy.
Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.
Alemtuzumab for multiple sclerosis.
Axon growth inhibition by RhoA/ROCK in the central nervous system.
Changes of CXCL12, CXCL14 and PDGF levels in the brain of patients with idiopathic demyelinating optic neuritis and neuromyelitis optica.
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
Review of the biology of multiple sclerosis.
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
High Intensity Exercise in Multiple Sclerosis: Effects on Muscle Contractile Characteristics and Exercise Capacity, a Randomised Controlled Trial.
Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy.
Basophils are dispensable for the recovery of gross locomotion after spinal cord hemisection injury.
Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors.
Possible Relations Between Epstein-Barr Virus Past Infection and Classic Multiple Sclerosis in Guilan, Iran.
Susceptibility Genes for Multiple Sclerosis Identified in a Gene-Based Genome-Wide Association Study.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Glia-neuron interactions in neurological diseases: Testing non-cell autonomy in a dish.
Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
Correction: Treatment with Vitamin D/MOG Association Suppresses Experimental Autoimmune Encephalomyelitis.
Stable biomarker for plastic microglia.
Pages
« first
‹ previous
…
698
699
700
701
702
703
704
705
706
…
next ›
last »